APBA2

Across TCGA pan-cancer cohorts, APBA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated APBA2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher APBA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APBA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, UCEC, and GBM are the cancer types where APBA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.994	0.667	.001	32	view →
UCEC	DFS	Median	All	1.000	0.933	.025	6	view →
GBM	OS	Quartile	All	0.920	0.727	.021	3	view →
LSCC	OS	Quartile	All	0.750	0.950	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

APBA2–LUAD (DFS)

Open the LUAD breakdown →